دورية أكاديمية
Radioactive Iodine: A Living History.
| العنوان: | Radioactive Iodine: A Living History. |
|---|---|
| المؤلفون: | Daniels GH; Thyroid Unit, Endocrine Tumor Center, Department of Medicine, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts, USA., Ross DS; Thyroid Unit, Endocrine Tumor Center, Department of Medicine, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts, USA. |
| المصدر: | Thyroid : official journal of the American Thyroid Association [Thyroid] 2023 Jun; Vol. 33 (6), pp. 666-673. |
| نوع المنشور: | Journal Article |
| اللغة: | English |
| بيانات الدورية: | Publisher: Mary Ann Liebert Publishers Country of Publication: United States NLM ID: 9104317 Publication Model: Print Cited Medium: Internet ISSN: 1557-9077 (Electronic) Linking ISSN: 10507256 NLM ISO Abbreviation: Thyroid Subsets: MEDLINE |
| أسماء مطبوعة: | Original Publication: New York, NY : Mary Ann Liebert Publishers, |
| مواضيع طبية MeSH: | Thyroid Neoplasms* , Graves Disease* , Hyperthyroidism*, Humans ; Iodine Radioisotopes ; Radiopharmaceuticals |
| مستخلص: | Background: Before the development of antithyroid drugs in the 1940s, treatment of Graves' hyperthyroidism was primarily surgical. Surgical mortality was quite variable, but a significant minority of patients died during or after surgery. Summary: In 1936, Karl Compton, President of the Massachusetts Institute of Technology, in a lecture attended by Massachusetts General Hospital physicians, suggested that artificially radioactive isotopes might be useful for studying metabolism. By 1942, Hertz and Roberts reported on the successful use of radioactive iodine (RAI) to treat Graves' hyperthyroidism. RAI uptake was subsequently demonstrated in well-differentiated thyroid cancer metastases. In 1948, Seidlin demonstrated stimulation of uptake in thyroid cancer metastases by thyrotropin (TSH). By 1990, 69% of endocrinologists in North America recommended RAI for Graves' hyperthyroidism. Currently RAI is less frequently used for Graves' hyperthyroidism, related to concerns about exacerbation of thyroid eye disease, about radiation exposure, and about potential adverse consequences of permanent hypothyroidism. Similarly, RAI was administered to the majority of patients with thyroid cancer for decades, but its use is now more selective. Conclusions: RAI is a remarkable example of interinstitutional cooperation between physicians and scientists to transition from bench to bedside in only three years. It is the model for a theranostic approach to disease (the simultaneous use of a radioactive drug for diagnosis and therapy). The future of RAI is less certain; inhibition of TSH receptor stimulating antibodies in Graves' disease and more precise targeting of genes that drive thyroid oncogenesis may diminish the use of RAI. Alternatively, redifferentiation techniques may improve the efficacy of RAI in RAI-refractory thyroid cancer. |
| فهرسة مساهمة: | Keywords: hyperthyroidism; radioactive iodine; thyroid cancer |
| المشرفين على المادة: | 0 (Iodine Radioisotopes) 0 (Radiopharmaceuticals) |
| تواريخ الأحداث: | Date Created: 20230612 Date Completed: 20230614 Latest Revision: 20230619 |
| رمز التحديث: | 20230620 |
| DOI: | 10.1089/thy.2022.0344 |
| PMID: | 37307104 |
| قاعدة البيانات: | MEDLINE |
| تدمد: | 1557-9077 |
|---|---|
| DOI: | 10.1089/thy.2022.0344 |